Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Atreca, Inc. | Chief Financial Officer | Class A Common Stock | 72.8K | $29.3K | $0.40 | Aug 2, 2023 | Direct |
Jasper Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 40K | Feb 15, 2024 | Direct | ||
Apexigen, Inc. | Director | Stock Option (right to buy) | 0 | Aug 23, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
JSPR | Jasper Therapeutics, Inc. | Feb 15, 2024 | 1 | $0 | 4 | Feb 20, 2024 | Chief Financial Officer |
JSPR | Jasper Therapeutics, Inc. | Sep 22, 2023 | 1 | $0 | 4 | Sep 26, 2023 | Chief Financial Officer |
JSPR | Jasper Therapeutics, Inc. | Sep 22, 2023 | 0 | $0 | 3 | Sep 26, 2023 | Chief Financial Officer |
APGN | Apexigen, Inc. | Aug 23, 2023 | 2 | $0 | 4 | Aug 25, 2023 | Director |
BCEL | Atreca, Inc. | Aug 2, 2023 | 1 | -$5.22K | 4 | Aug 4, 2023 | Chief Financial Officer |
BCEL | Atreca, Inc. | Feb 9, 2023 | 2 | $0 | 4 | Feb 13, 2023 | Chief Financial Officer |
APGN | Apexigen, Inc. | Sep 29, 2022 | 1 | $0 | 4 | Oct 3, 2022 | Director |
BCEL | Atreca, Inc. | Sep 2, 2022 | 1 | -$13.6K | 4 | Sep 20, 2022 | Chief Financial Officer |
APGN | Apexigen, Inc. | Jul 29, 2022 | 0 | $0 | 3 | Aug 8, 2022 | Director |
BCEL | Atreca, Inc. | Jun 13, 2022 | 6 | $0 | 4 | Jun 15, 2022 | Chief Financial Officer |
BCEL | Atreca, Inc. | Dec 23, 2021 | 1 | $0 | 4 | Dec 28, 2021 | Chief Financial Officer |
BCEL | Atreca, Inc. | Sep 9, 2021 | 1 | $0 | 4 | Sep 13, 2021 | Chief Financial Officer |